Janssen Announces Comprehensive 2-Year Data from DISCOVER–2 trial of Tremfya (guselkumab) in Patients with Psoriatic Arthritis Published in Arthritis & Rheumatology

Janssen Announces Comprehensive 2-Year Data from DISCOVER–2 trial of Tremfya (guselkumab) in Patients with Psoriatic Arthritis Published in Arthritis & Rheumatology

Janssen announced comprehensive efficacy and safety data from the DISCOVER–2 trial of Tremfya (guselkumab) were published in Arthritis & Rheumatology, representing the final results of the first two-year clinical trial in patients with active psoriatic arthritis (PsA). Data demonstrated low rates of structural damage progression and durable improvements in physical function at week 100. In addition, approximately 80-90 percent of Tremfya-treated patients who achieved improvements in joint signs and symptoms and low levels of disease activity at week 52 (ACR20/50 and MDA) maintained this response at week 100.

The randomized, double-blind, multicenter Phase 3 study evaluated the efficacy and safety of Tremfya administered by subcutaneous (SC) injection in biologic-naïve patients with active PsA. The trial enrolled 739 patients who were treated every 4 weeks (q4w) or every 8 weeks (q8w) or placebo and followed through approximately two years. The primary endpoint was response of ACR20 at week 24, for which the data was previously reported.   

The comprehensive two-year data revealed durable improvement in joint manifestations and skin clearance:  

Among Tremfya...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee